Zydus’ Usnoflast Receives FDA Fast Track for ALS

  Published 1 year ago

Zydus Lifesciences’ Usnoflast (ZYIL1), a novel NLRP3 inhibitor, has received Fast Track Designation from the USFDA for treating ALS. This, alongside Orphan Drug Designation, accelerates development for this serious, unmet medical need.

  • ALS affects ~32K in the US & 75K in India.
  • Usnoflast is in Phase 2(b) trials, following positive Phase 2(a) data.
  • Fast Track offers benefits like priority review & FDA interaction.

You might like these

Arvind Fashions Q1 Profit Soars 10x

RBI Currency & Reserve Money Update

FADA: Mixed Vehicle Sales Growth in Q1 FY26

India's Manufacturing Sector Gains Momentum in June 2024

ITD Cementation Soars 6.93% on Rs 893 Crore Order

TVS Motor to Cut Prices

India's Textiles Task Force Aims to Boost Exports

News that matters the most ⚡